Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.05.040
- VernacularTitle:不同抗病毒药物降低HBV相关肝细胞癌风险的作用
- Author:
Lixian WU
1
;
Weiqiang ZHENG
1
;
Huanqin HAN
1
Author Information
1. Department of Infectious Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China
- Publication Type:Reviews
- Keywords:
Hepatitis B virus;
Carcinoma, Hepatocellular;
Antiviral Agents
- From:
Journal of Clinical Hepatology
2022;38(5):1165-1168
- CountryChina
- Language:Chinese
-
Abstract:
Antiviral therapy can reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. As for the first-line antiviral drugs, more studies have shown that tenofovir disoproxil fumarate may be better than entecavir in reducing the risk of HCC, especially among Asian patients; a limited number of studies have shown that tenofovir alafenamide fumarate may be better than tenofovir disoproxil fumarate in reducing the risk of HCC; interferon has a better effect than nucleos(t)ide analogues alone in reducing the risk of HCC. Among the currently available drugs, interferon combined with nucleos(t)ide analogues may be the best choice to reduce the risk of HCC in patients at a high risk of HCC. The level of evidence-based medicine is weak for comparing the effect of different drugs in reducing the risk of HCC, and randomized controlled trials are needed for further clarification. In practice, it is necessary to weigh the risk of HCC, drug tolerance and economic affordability based on the patient's basic conditions and actual situations, so as to develop individualized anti-viral strategies.
